Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

Sergio D. Bergese, Sonia Ramamoorthy, Gary Patou, Kenneth Bramlett, Stephen R. Gorfine, Keith A Candiotti

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. Results: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalJournal of Pain Research
Volume5
DOIs
StatePublished - Dec 1 2012

Fingerprint

Bupivacaine
Liposomes
Analgesia
Opioid Analgesics
Pain
Wounds and Injuries
Local Anesthetics
Orthopedics
Patient Care
Therapeutics

Keywords

  • Analgesic
  • Local anesthetic
  • Pain
  • Postsurgical
  • Wound infiltration

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia. / Bergese, Sergio D.; Ramamoorthy, Sonia; Patou, Gary; Bramlett, Kenneth; Gorfine, Stephen R.; Candiotti, Keith A.

In: Journal of Pain Research, Vol. 5, 01.12.2012, p. 107-116.

Research output: Contribution to journalArticle

Bergese, Sergio D. ; Ramamoorthy, Sonia ; Patou, Gary ; Bramlett, Kenneth ; Gorfine, Stephen R. ; Candiotti, Keith A. / Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia. In: Journal of Pain Research. 2012 ; Vol. 5. pp. 107-116.
@article{59f30d6a8bae42f2842af114307fb30d,
title = "Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia",
abstract = "Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. Results: Overall, 45{\%} of patients were male and 19{\%} were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.",
keywords = "Analgesic, Local anesthetic, Pain, Postsurgical, Wound infiltration",
author = "Bergese, {Sergio D.} and Sonia Ramamoorthy and Gary Patou and Kenneth Bramlett and Gorfine, {Stephen R.} and Candiotti, {Keith A}",
year = "2012",
month = "12",
day = "1",
doi = "10.2147/JPR.S30861",
language = "English",
volume = "5",
pages = "107--116",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

AU - Bergese, Sergio D.

AU - Ramamoorthy, Sonia

AU - Patou, Gary

AU - Bramlett, Kenneth

AU - Gorfine, Stephen R.

AU - Candiotti, Keith A

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. Results: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.

AB - Background: Liposome bupivacaine is a novel formulation of the local anesthetic bupivacaine, designed to provide prolonged postsurgical analgesia. This analysis examined pooled efficacy data as reflected in cumulative pain scores from 10 randomized, double-blind liposome bupivacaine clinical studies in which the study drug was administered via local wound infiltration. Methods: A total of 823 patients were exposed to liposome bupivacaine in 10 local wound infiltration studies at doses ranging from 66 mg to 532 mg in five surgical settings; 446 patients received bupivacaine HCl (dose: 75-200 mg) and 190 received placebo. Efficacy measures were assessed through 72 hours after surgery. Results: Overall, 45% of patients were male and 19% were ≥65 years of age. In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms. These results were supported by results of other efficacy measures, including time to first use of opioid rescue medication, proportion of patients avoiding opioid rescue medication, total postsurgical consumption of opioid rescue medication, and patient/care provider satisfaction with postoperative analgesia. Local infiltration of liposome bupivacaine resulted in significant systemic plasma levels of bupivacaine, which could persist for 96 hours; systemic plasma levels of bupivacaine following administration of liposome bupivacaine were not correlated with local efficacy. Liposome bupivacaine and bupivacaine HCl were generally well tolerated. Conclusion: Based on this integrated analysis of multiple efficacy measures, liposome bupivacaine appears to be a potentially useful therapeutic option for prolonged reduction of postsurgical pain in soft tissue and orthopedic surgeries.

KW - Analgesic

KW - Local anesthetic

KW - Pain

KW - Postsurgical

KW - Wound infiltration

UR - http://www.scopus.com/inward/record.url?scp=84867875301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867875301&partnerID=8YFLogxK

U2 - 10.2147/JPR.S30861

DO - 10.2147/JPR.S30861

M3 - Article

C2 - 22570563

AN - SCOPUS:84867875301

VL - 5

SP - 107

EP - 116

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -